Abstract YO10
Case summary
A 22y/female
No comorbidities
No family history of any malignancy
Presented with complaints of mass P/R from December 2014
Initially patient was on alternative medication with an opinion of hemorrhoids
In October 2015 in view of increased symptoms got evaluated and U/W Sigmoidoscopy and found to have growth
2/12/15 U/W Polypectomy
HPR S/O Follicular dendritic cell sarcoma with negative margins
21/12/15 CECT S/O no abnormality , though patient was planned for surgery with revision of margins opted for observation
July 2016 Patient is asymptomatic and on follow up found to have (USG and CT further) multiple liver metastases with Bx consistent with same.
Received 4# CHOP till 17/11/16
Dec 2016 CT S.O Increase in number and size of hepatic metastases
Started on Gemcitabine+Docetaxel 6# with interim assessment S.O partial response and further mainatined.
11/9/17 U.W RFA of Segment VIII of right lobe and Segment III of left lobe of liver.
Received 2# more Gemciatbine+Docetaxel till 20/10/17
November 2017 PET CT S/O Complete metabolic response and kept on observation
9/3/18 Evaluated for abdominal discomfort and S.O liver lesions in segment IVb and Segment V lesions
15/3/18 IVb and V lesion coiling was done and kept on observation
May 2018 Significant increase in number and size of lesions and was started on Tab.Capecitabine 500mg BD+Tab.Sorafenib 400mg BD
July 2018 Response assessment was done S/O increase in size of lesions with maximum lesion size increased from 3.9----->6 cms
Started on Tab.Pazopanib +Tamoxifen
October 2018 response assessment was done S/O Partial response with decrease in size and enhancement
27/12/18 U/W resection of liver IVb/V segments and Pazopanib+Tamoxifen were continued as an adjuvant from January 2019 to April 2019
Lost to follow up for 2 months and stopped medications from 2 months
13/6/19 Asymptomatic but CT S/O two new lesions in liver segment VII 2.1x 1.4cms and 1.2x1.2 cms were noted.
CURRENT STATUS : Restarted on Tab.Pazopanib 400mg BD and planned for RFA further
Clinical trial identification
Editorial acknowledgement
Resources from the same session
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract